← Back to Search

Anti-metabolites

Avastin + Alimta + Carboplatin for Lung Cancer

Phase 2
Waitlist Available
Led By James Stevenson, M.D.
Research Sponsored by The Cooper Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
I am not on heparin, coumadin or lovonox for treatment of medical conditions
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will study the combination of Avastin, Alimta, and Carboplatin as front-line therapy for patients with advanced nonsquamous non-small cell lung cancer.

Who is the study for?
This trial is for adults over 18 with advanced non-squamous non-small cell lung cancer who haven't had major surgery in the last 28 days or previous treatment, except radiation. Participants should not be on certain blood thinners and must have controlled high blood pressure without serious wound healing issues.Check my eligibility
What is being tested?
The study tests a combination of Avastin, Alimta, and Carboplatin as initial therapy for patients with this type of lung cancer. Avastin is an antiangiogenic agent that cuts off blood supply to tumors, while Alimta and Carboplatin are chemotherapy drugs.See study design
What are the potential side effects?
Possible side effects include increased risk of bleeding due to Avastin's effect on blood vessels, nerve damage from Carboplatin, and fatigue or skin rash from Alimta. Each drug can also lower white blood cell counts increasing infection risk.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am not taking heparin, coumadin, or lovonox.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

The Cooper Health SystemLead Sponsor
75 Previous Clinical Trials
24,113 Total Patients Enrolled
James Stevenson, M.D.Principal InvestigatorThe Cooper Health System

Media Library

Alimta (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT00254319 — Phase 2
Non-Small Cell Lung Cancer Research Study Groups:
Non-Small Cell Lung Cancer Clinical Trial 2023: Alimta Highlights & Side Effects. Trial Name: NCT00254319 — Phase 2
Alimta (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00254319 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this therapy been given the stamp of approval from the FDA?

"Our team at Power ranked the safety of this treatment a 2, due to Phase 2 trial data only providing evidence for its safety and not efficacy."

Answered by AI

Is the eligibility for this clinical experiment restricted to a particular age bracket?

"This trial is recruiting individuals aged 18 to 65."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
2024. "Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00254319.
All > Lung > Sclc
~233 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top